On December 22, 2015, Duan Yiqian, the head of purchasing management of marketing department in Huarun Pharmaceutical Group, and a group of people came to CHIPSCREEN BIOSCIENCES to meet and exchange views. Lu Xianping, the president of the company, and He Ming, the manager of the Brand Ministry of Commerce, attended the meeting.

At the meeting, Dr. Lu first thanked the colleagues of Huarun Pharmaceutical Group for visiting CHIPSCREEN BIOSCIENCES. He said that Huarun Pharmaceutical Group has rich channel resources and is making efforts to carry out strategic transfer to new technologies and high-tech industries. CHIPSCREEN BIOSCIENCES focuses on original new medicines, so it is very much looking forward to establishing a long-term strategic partnership with Huarun Pharmaceutical Group.

Subsequently, Duan Yiqian, the head of purchasing management in Huarun Pharmaceutical Group, said that at present, through the analysis of big data, they clearly found that the growth rate of growth-type pharmaceutical enterprises was significantly higher than that of large traditional pharmaceutical enterprises, especially those scientific and technological pharmaceutical enterprises with independent intellectual property rights. However, growth-type enterprises were unable to enter the hospital quickly due to the barriers of other factors such as medical insurance and basic medicine catalogues in the early stage of the sale of new drugs, and there were fewer patients in general. Huarun Pharmaceutical Group is working hard to open the last kilometer of the road for drug companies to reach their patients so that new specialty drugs can be delivered to their patients as soon as possible, benefiting both  enterprises and humans.

Then, He Ming from the Ministry of Commerce made a report on CHIPSCREEN BIOSCIENCES and its product line, and the two sides had friendly discussions and exchanges on the market prospect of the following series of product lines.